NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.95 +0.47 (+0.60%) GOLD FUTURES
2,325.40 -5.80 (-0.25%) DOW
38,914.77 +62.50 (+0.16%) Bitcoin GBP
50,692.91 +367.44 (+0.73%)
Merus N.V. (MRUS)
- GlobeNewswire
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
If approved, Zeno will be the first targeted therapy for NRG1+ cancerUTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for the bispecific antibody zen
- Zacks
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
Merus (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
